Controlled delivery of follicle-stimulating hormone in cattle

[Display omitted] •Embryo transfer in cattle using superovulation is an important process.•Several intramuscular injections of follicle-stimulating hormone are usually required.•Sustained-release formulations reduce workload, technical errors and animal stress.•Superovulation is performed by differe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2020-11, Vol.590, p.119904-119904, Article 119904
Hauptverfasser: Deguettes, Quentin, Fattal, Elias, Moreau, Marinette, Lego, Elodie, Bochot, Amélie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Embryo transfer in cattle using superovulation is an important process.•Several intramuscular injections of follicle-stimulating hormone are usually required.•Sustained-release formulations reduce workload, technical errors and animal stress.•Superovulation is performed by different formulation approaches.•Manufacturing complexity and cost should be considered for new veterinary products. Embryo transfer in cattle is a key issue requiring in vivo production of several mature follicles as opposed to the normal production of only one. In vivo produced embryos can then be transferred to recipient cows for gestation to occur. To obtain a large number of transferable embryos, the superovulation step is crucial. To allow the growth of ovarian follicles, the most commonly used protocol consists of 2 intramuscular injections per day over 4 days of a saline solution of the follicle-stimulating hormone. To reduce workload, technical errors in the injected dose and animal stress, different strategies have been investigated to sustain the release of this hormone over 4 days in 1 or 2 injections. This review introduces the physicochemical properties of the follicle-stimulating hormone and discusses the limitations of marketed products and all the research that has been conducted to overcome these limitations. In particular, the field of subcutaneous administrations, the development of new formulations such as viscous solutions, implants and microspheres and the modification of the structure of the follicle-stimulating hormone are overviewed and discussed.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2020.119904